US55279B3015 - MEIP - A3D69W (XNCM)
MEI PHARMA INC. Aktie
2,75 EUR
Aktuelle Kurse von MEI PHARMA INC.
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
MEIP
|
USD
|
20.09.2024 17:19
|
3,07 USD
| 3,08 USD | -0,29 % |
London |
0JW9.L
|
USD
|
19.09.2024 15:30
|
3,15 USD
| 3,16 USD | -0,32 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
-4,21 % | 0,61 % | -1,20 % | 4,10 % | -19,19 % | -50,25 % | -92,18 % |
Firmenprofil zu MEI PHARMA INC. Aktie
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Unternehmensdaten zur MEI PHARMA INC. Aktie
Name MEI PHARMA INC.
Firma MEI Pharma, Inc.
Symbol MEIP
Website https://www.meipharma.com
Heimatbörse
Frankfurt
WKN A3D69W
ISIN US55279B3015
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Justin J. File
Marktkapitalisierung 21 Mio
Land Vereinigte Staaten von Amerika
Währung EUR
Mitarbeiter 0,0 T
Adresse 11455 El Camino Real, 92130 San Diego
IPO Datum 2003-12-18
Dividenden von MEI PHARMA INC.
Ex-Datum | Dividende pro Aktie |
---|---|
16.11.2023 | 1,75 USD |
Aktien Kennungs-Wechsel
Datum | Von | Zu |
---|---|---|
01.12.2015 | MSHL | MEIP |
Ticker Symbole
Name | Symbol |
---|---|
London | 0JW9.L |
NASDAQ | MEIP |
Weitere Aktien
Investoren die MEI PHARMA INC. halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024